Travere Therapeutics, Inc. 4

Director-level insider Roy D. Baynes exercised 4,500 stock options and sold 4,500 Travere Therapeutics (TVTX) common shares for about $225,000 on June 12, 2026 under a Rule 10b5-1 plan.

On June 12, 2026, Travere Therapeutics, Inc. insider Roy D. Baynes exercised 4,500 stock options at an exercise price of $21.38 per share and immediately sold 4,500 shares of common stock at $50.00 per share pursuant to a Rule 10b5-1 trading plan, resulting in an estimated gross sale value of $225,000 and option exercise cost of about $96,210. Following these transactions, his direct ownership in Travere common stock decreased from 46,000 to 41,500 shares, implying an unchanged economic exposure only to the extent of the net shares retained historically, as this specific exercise was fully offset by the same-day sale of the underlying shares.

Filing Facts

CIK

1438533

Ticker

TVTX

Form

4

Source Type

sec

Accession

0001680739-26-000014

Alert Tier

5